30

Yili Chuanning Biotechnology Co. Ltd. A

301301 · SHE · Healthcare / Biotechnology

7.61CNY-0.17 (-2.19%)

Price History

Full chart

Market Stats

Previous Close7.78
Open7.78
Day Range7.60 – 7.84
52-Week Range7.69 – 12.67
Volume6.58M
Market Cap18.28B
P/E (TTM)31.50
Forward P/E0.00
EPS0.26
Dividend Yield2.11%
Beta0.01
50-Day Avg8.57
200-Day Avg9.70

About

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ectoine, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop cultivation, detection, technical consultation, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Xuheng Deng
  • Employees3.13K
  • HeadquartersNo. 1 Gongchen Road, Yining, China, 835000, China
  • Websitehttps://www.klcnsw.com

Leadership

  • Mr. Xuheng DengGM & Director · b. 1987
  • Mr. Yixing LiDeputy GM, CFO & Director · b. 1984
  • Mr. Zhao HuaDeputy GM & Chief Scientist · b. 1970
  • Mr. Xiang GuDeputy GM & Secretary · b. 1992
  • Mr. Hai JiangDeputy General Manager · b. 1982
  • Mr. Yun Peng ShenDeputy General Manager · b. 1972
  • Yan NiuAccounting Supervisor

Financials

Income Statement

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.23B3.82B4.82B5.76B4.62B
Growth (%)-+18.21%+26.24%+19.38%-19.83%
Cost of Revenue2.51B2.87B3.30B3.66B3.27B
Gross Profit717.93M947.44M1.52B2.10B1.35B
Gross Margin22.21%24.80%31.57%36.39%29.25%
Operating Expense309.65M239.53M278.16M339.54M329.74M
Operating Income408.28M707.91M1.24B1.76B1.02B
Operating Margin12.63%18.53%25.81%30.49%22.11%
EBITDA-1.18B1.76B2.28B1.56B
EBITDA Margin-30.82%36.40%39.56%33.79%
Net Income111.35M411.52M940.56M1.40B769.01M
Net Income Margin3.45%10.77%19.50%24.32%16.66%
R&D32.95M35.38M55.26M77.73M102.49M
R&D as % of Total Revenue1.02%0.93%1.15%1.35%2.22%
Interest Expense9.29M142.34M87.78M44.21M33.82M
Interest Expense % of Total Revenue0.29%3.73%1.82%0.77%0.73%

Balance Sheet

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.46B10.39B10.14B10.55B10.43B
Total Liabilities4.68B4.18B3.17B2.64B2.32B
Total Equity4.77B6.20B6.96B7.90B8.08B
Cash510.05M1.63B760.94M1.09B734.21M
Net Debt2.28B774.80M447.08M--

Cash Flow

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow803.21M691.64M1.29B1.79B549.06M
Capital Expenditure52.27M47.20M345.13M42.60M97.21M
Free Cash Flow750.94M644.44M947.26M1.75B451.85M
Dividends Paid167.80M142.82M290.12M545.07M622.10M
FCF to OCF93.49%93.18%73.30%97.62%82.29%
Dividend Paid to FCF22.34%22.16%30.63%31.17%137.68%

Earnings

Report DateMar 12, 2023Apr 24, 2023Aug 21, 2023Oct 23, 2023Dec 31, 2023Apr 10, 2024Aug 26, 2024Sep 30, 2024Dec 31, 2024Apr 28, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------
EPS Actual0.040.080.100.110.140.160.190.140.150.130.070.070.070.050.07
Surprise---------------
TimingPre-marketPre-marketAfter-hoursPre-market-Pre-marketPre-market--Pre-market-----

Key Statistics & Ratios

Market Cap18.28B
Enterprise Value18.29B
Trailing P/E31.50
Forward P/E0.00
Price / Sales4.19
Price / Book2.27
EPS0.26
Book Value3.58
Revenue (TTM)4.37B
Gross Profit (TTM)1.05B
EBITDA1.32B
Profit Margin13.55%
Operating Margin20.88%
Return on Equity7.45%
Return on Assets4.54%
Shares Outstanding2.23B
Shares Float527.20M
Beta0.01
Dividend Yield2.11%
Dividend Rate0.17
Payout Ratio65.21%

Dividends

20261×
0.17Apr 29, 2026
20251×
0.27Jun 10, 2025
20241×
0.22May 22, 2024
20231×
0.09May 29, 2023